公开(公告)号：US20240315998A1

公开(公告)日：2024-09-26

申请号：US18677822

申请日：2024-05-29

申请人： FILTRICINE, INC.

发明人： Xiyan Li ,  Xin Wang ,  Xiaolu Yang

IPC分类号： A61K31/198 ,  A61K31/07 ,  A61K31/14 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/04 ,  A61K33/16 ,  A61K33/18 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34

CPC分类号： A61K31/198 ,  A61K31/07 ,  A61K31/14 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/04 ,  A61K33/16 ,  A61K33/18 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34

摘要： The present disclosure provides compositions and methods for treating cancer with nutritionally modified diets and/or dialysis treatment, such as through amino acid depletion of one or more nonessential amino acids. In some aspects, the present disclosure provides compositions and methods for treating obesity with such modified diets and/or dialysis treatment. Furthermore, in some aspects, the present disclosure provides compositions and methods for treating renal disease with such modified diets and/or dialysis treatment.

公开(公告)号：US20240307476A1

公开(公告)日：2024-09-19

申请号：US18273947

申请日：2022-02-15

申请人： PM-INTERNATIONAL AG

发明人： Rolf Sorg ,  Tobias Kühne ,  Wilhelm Messer

IPC分类号： A61K36/73 ,  A23L2/39 ,  A23L2/56 ,  A23L2/60 ,  A23L2/68 ,  A61K9/00 ,  A61K31/197 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/714 ,  A61K33/30 ,  A61K36/258 ,  A61K36/87 ,  A61K36/88 ,  A61K36/906 ,  A61K47/12 ,  A61K47/26

CPC分类号： A61K36/73 ,  A23L2/39 ,  A23L2/56 ,  A23L2/60 ,  A23L2/68 ,  A61K9/0095 ,  A61K31/197 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/714 ,  A61K33/30 ,  A61K36/258 ,  A61K36/87 ,  A61K36/88 ,  A61K36/906 ,  A61K47/12 ,  A61K47/26

摘要： A powdered dietary supplement, containing a) 50 to 90% by weight of at least one saccharide, b) 2 to 20% by weight of apple extract, wine grape extract and saffron, c) at least one herbal extract selected from ginger extract, ginseng extract and pepper extract, d) at least one zinc compound, e) at least two B group vitamins, and f) at least one acidifying agent.

公开(公告)号：US20240285704A1

公开(公告)日：2024-08-29

申请号：US18406671

申请日：2024-01-08

申请人： FP Nutraceuticals, LLC

发明人： Timothy M. Marshall

IPC分类号： A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/00 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45

CPC分类号： A61K36/185 ,  A23L33/105 ,  A23L33/115 ,  A23L33/125 ,  A23L33/155 ,  A23L33/16 ,  A23L33/165 ,  A23L33/175 ,  A61K9/0056 ,  A61K31/015 ,  A61K31/05 ,  A61K31/07 ,  A61K31/122 ,  A61K31/145 ,  A61K31/16 ,  A61K31/192 ,  A61K31/194 ,  A61K31/198 ,  A61K31/232 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/525 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/69 ,  A61K31/714 ,  A61K33/06 ,  A61K33/18 ,  A61K36/03 ,  A61K36/42 ,  A61K36/45 ,  A23V2002/00

摘要： The compositions of this disclosure provide broad-spectrum nutrient supplementation to support the health of multiple organ and tissue systems in which mitochondrial function plays a fundamental role. In particular, the formulations promote neuroprotective, cardioprotective, immunosupportive, and anti-aging benefits. Also provided herein are novel, neuroprotective preparations containing a combination of broad- or full-spectrum hemp oil extract combined with niacinamide, a non-flushing form of vitamin B3, and methods of use are described allowing for safe, effective, and convenient use of a neuroprotective, antioxidant preparation for general and clinical use.

公开(公告)号：US20240277672A1

公开(公告)日：2024-08-22

申请号：US18403028

申请日：2024-01-03

申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

发明人： Geert-Jan Boons

IPC分类号： A61K31/4188 ,  A61K47/68 ,  A61K49/00 ,  C07K16/00 ,  C07K16/28

CPC分类号： A61K31/4188 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6849 ,  A61K49/0043 ,  A61K49/0058 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2317/92

摘要： Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.

公开(公告)号：US12023317B2

公开(公告)日：2024-07-02

申请号：US17687682

申请日：2022-03-07

申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Jin Chul Kim ,  Jung Yeob Ham ,  Tae Jung Kim ,  Dorjsembe Banzragch ,  Ha Neul Ju ,  Hyung Seok Yu

IPC分类号： A61K31/365 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/07 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K36/73 ,  A61K47/12 ,  A61K47/20 ,  A61P37/06

CPC分类号： A61K31/365 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/1623 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2059 ,  A61K31/07 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K36/73 ,  A61K47/12 ,  A61K47/20 ,  A61P37/06 ,  A61K2236/331 ,  A61K2236/333

摘要： Disclosed is a composition for use in preventing, alleviating, or treating psoriasis containing cimicifugolide A as an active ingredient.

公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

申请人： ABBOTT LABORATORIES

发明人： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC分类号： A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC分类号： A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

摘要： Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20240173301A1

公开(公告)日：2024-05-30

申请号：US18551793

申请日：2022-03-23

申请人： NEUROPHYXIA B.V.

发明人： Ido Remy VAN DEN WIJNGAARD ,  Cacha Marie Pétronelle Cathérine Dorothée PEETERS

IPC分类号： A61K31/4188 ,  A61K38/49

CPC分类号： A61K31/4188 ,  A61K38/49 ,  C12Y304/21068

摘要： The invention relates to the field of medicine. In particular, the present invention relates to the use of 2-iminobiotin for use in the treatment of stroke, wherein 2-iminobiotin is administered in combination with a fibrinolytic drug. The invention in particular relates to the use of 2-iminobiotin for use in the treatment of acute ischemic stroke is due to vessel occlusion eligible for endovascular mechanical thrombectomy.

公开(公告)号：US20240156749A1

公开(公告)日：2024-05-16

申请号：US18388554

申请日：2023-11-10

申请人： Maravilla, LLC

发明人： James M. STRINGHAM

IPC分类号： A61K31/047 ,  A23L33/00 ,  A61K9/00 ,  A61K31/07 ,  A61K31/14 ,  A61K31/197 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/04 ,  A61K33/06 ,  A61K33/18 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K36/9068

CPC分类号： A61K31/047 ,  A23L33/40 ,  A61K9/0056 ,  A61K31/07 ,  A61K31/14 ,  A61K31/197 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/04 ,  A61K33/06 ,  A61K33/18 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K36/9068

摘要： A dietary supplement includes a xanthophyll carotenoid including lutein, zeaxanthin, and meso-zeaxanthin. The dietary supplement may include, for example, greater than or equal to about 0.27 weight percent to less than or equal to about 0.47 weight percent of lutein, greater than or equal to about 0.066 weight percent to less than or equal to about 0.84 weight percent of zeaxanthin, and greater than or equal to about 0.27 weight percent to less than or equal to about 0.47 weight percent of meso-zeaxanthin.

公开(公告)号：US11970436B2

公开(公告)日：2024-04-30

申请号：US17749293

申请日：2022-05-20

申请人： NEONC Technologies, Inc.

发明人： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC分类号： C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16

CPC分类号： C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07B2200/07 ,  C07C2601/16 ,  C07C29/92 ,  C07C33/14 ,  C07C201/12 ,  C07C205/57 ,  C07C67/14 ,  C07C69/76 ,  C07C67/14 ,  C07C69/92

摘要： The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20240122918A1

公开(公告)日：2024-04-18

申请号：US18380984

申请日：2023-10-17

申请人： University of Cincinnati ,  The Johns Hopkins University

发明人： Andrew Steckl ,  Daewoo Han ,  Betty M. Tyler ,  Henry Brem ,  Safwan Alomari

IPC分类号： A61K31/473 ,  A61K9/70 ,  A61K31/277 ,  A61K31/4188 ,  A61K47/34 ,  B23K26/38 ,  B32B5/02 ,  B32B5/26 ,  B32B37/10 ,  B32B37/18 ,  B32B38/00 ,  B32B38/18 ,  D04H1/435 ,  D04H1/4382 ,  D04H1/56 ,  D04H1/728 ,  D06C15/00

CPC分类号： A61K31/473 ,  A61K9/7007 ,  A61K31/277 ,  A61K31/4188 ,  A61K47/34 ,  B23K26/38 ,  B32B5/022 ,  B32B5/266 ,  B32B37/1045 ,  B32B37/18 ,  B32B38/0004 ,  B32B38/0008 ,  B32B38/18 ,  D04H1/435 ,  D04H1/43828 ,  D04H1/43838 ,  D04H1/56 ,  D04H1/728 ,  D06C15/00 ,  B32B2250/20 ,  B32B2255/02 ,  B32B2255/26 ,  B32B2262/0276 ,  B32B2262/124 ,  B32B2305/28 ,  B32B2309/02 ,  B32B2310/0843 ,  B32B2367/00 ,  B32B2535/00 ,  D10B2331/041 ,  D10B2331/30 ,  D10B2509/00

摘要： A drug delivery device comprising: a first layer comprising a first coaxially electrospun nanofiber membrane; a second layer comprising a second coaxially electrospun nanofiber membrane; a first therapeutic agent integrated into the first coaxially electrospun nanofiber membrane; and a second therapeutic agent integrated into the second coaxially electrospun nanofiber membrane. The second therapeutic agent is different from the first therapeutic agent.